P159 New kids on the block - real-world experience of using belimumab, obinutuzumab and voclosporin in systemic lupus erythematosus. A retrospective cohort study in University College London Hospital
Retrospective analysis reveals effective use of belimumab and obinutuzumab in SLE, suggesting need for more voclosporin data.
Key Points
To evaluate the real-world use and outcomes of belimumab, obinutuzumab, and voclosporin in systemic lupus erythematosus patients.
Retrospective cohort study with SLE patients treated with belimumab (n=25), obinutuzumab (n=8), and voclosporin (n=3) for at least six months.
Clinical response assessed using the BILAG-2004 disease activity index at multiple time points.
Serological response evaluated through anti-dsDNA antibody titres and C3 levels, renal response by serum creatinine and urine protein-to-creatinine ratio.
Belimumab showed significant clinical improvement with BILAG score decreasing and anti-dsDNA antibody titres reducing by 51%.
Obinutuzumab resulted in decreased BILAG score and improvement in renal parameters; however, the significance of C3 increase remains unclear.
Voclosporin demonstrated mixed results with some improvement metrics but rising creatinine levels raised concerns.